Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

144 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Nampa, Idaho, United States
  • GSK Investigational Site Louisville, Kentucky, United States
  • GSK Investigational Site Baltimore, Maryland, United States
View all 37 locations
View Trial Details
Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

NCT04657198

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Lenexa, Kansas, United States
  • GSK Investigational Site Elkridge, Maryland, United States
  • GSK Investigational Site Omaha, Nebraska, United States
  • GSK Investigational Site Rochester, New York, United States
View Trial Details
Completed

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

NCT02247726

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Advanced Specialty Research Nampa, Idaho, United States
  • Hutchinson Clinic, P.A. Hutchinson, Kansas, United States
  • University of Kansas Medical Center Research Institute Kansas City, Kansas, United States
  • Meridian Clinical Research Norfolk, Nebraska, United States
View Trial Details
Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03227029

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program La Jolla, California, United States
  • Usc La Nichd Crs Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA NICHD CRS Los Angeles, California, United States
  • Univ. of Colorado Denver NICHD CRS Aurora, Colorado, United States
View Trial Details
Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03102034

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Usc La Nichd Crs Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA NICHD CRS Los Angeles, California, United States
  • Univ. of Colorado Denver NICHD CRS Aurora, Colorado, United States
  • Emory University School of Medicine NICHD CRS Atlanta, Georgia, United States
View Trial Details
Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Huntington Park, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Nampa, Idaho, United States
View all 32 locations
View Trial Details
Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Anaheim, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Topeka, Kansas, United States
  • GSK Investigational Site Frederick, Maryland, United States
View all 24 locations
View Trial Details

Related conditions